Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
290 Leser
Artikel bewerten:
(1)

Panoramic Health Elevates Kidney Care Innovation With Appointment of Dr. Navdeep Tangri as Senior Advisor for Panoramic Science

Renowned Nephrologist and Researcher Will Support Panoramic Health's Efforts to Redefine the Standard of Kidney Care Through Novel Therapies

TEMPE, AZ / ACCESSWIRE / May 29, 2024 / Building on its commitment to pioneering advancements in kidney care, Panoramic Health, the nation's largest integrated nephrology practice network, proudly announces the appointment of Dr. Navdeep Tangri as Senior Advisor for Panoramic Science. This appointment marks a significant milestone for Panoramic Science following the establishment of its esteemed Scientific Advisory Board earlier this year.

Panoramic Health Logo

Panoramic Health Logo

Dr. Tangri is an award-winning nephrologist, professor, and scientist, whose efforts in understanding chronic kidney disease (CKD) led to the development of the Kidney Failure Risk Equation (KFRE), used worldwide to predict the need for dialysis in patients with CKD. He is currently an attending physician and Professor in the Division of Nephrology, Department of Medicine and the Department of Community Health Sciences at the University of Manitoba in Winnipeg.

"When Dr. Tangri and I started having regular conversations over a year ago, our clinical research business was nascent," said Dr. Rajiv Poduval, Co-Founder and Executive Chairman of Panoramic Health. "We have built considerable momentum since and are excited to have Nav be part of our journey. We're incredibly fortunate to have him on board, and his expertise and passion for innovation will undoubtedly help us drive transformative advancements in kidney care in partnership with pharma sponsors, benefitting countless patients."

Panoramic Science bridges the gap between clinical care and groundbreaking research. Through our vast network of integrated partner practices, we offer clinical research organizations and pharmaceutical sponsors a turnkey solution for executing Phase 2-4 regulated clinical trials for medications and devices awaiting FDA approval. Our partner providers have long-standing relationships with more than 300,000 patients, allowing for the rapid development and qualification of accurate patient eligibility lists with the ability to screen for co-morbid conditions.

"My primary research interest revolves around improving outcomes for patients with chronic kidney disease, which dovetails nicely with the work that Panoramic Health is doing through Panoramic Science," commented Dr. Navdeep Tangri. "I am excited to join the team as a Senior Advisor, and I look forward to seeing how our partnership can bring cutting-edge treatment options to kidney disease patients all over the globe."

Panoramic Health is confident that Dr. Tangri's appointment will further strengthen its position as a leader in kidney care innovation. By leveraging his expertise and insights, Panoramic Health is poised to accelerate the development of novel therapies and deliver impactful solutions to patients with kidney disease. To learn more about Panoramic Science, visit our website.

About Panoramic Health

Panoramic Health is kidney care's leading integrated provider group, with over 750 aligned providers across 19 states serving over 300,000 patients. We are committed to improving outcomes for patients by slowing disease progression and improving quality of life, keeping patients healthier, longer-at-home, and out of the hospital. At the core of our success lies the deep integration with partner nephrologists and the distinctive capabilities of our physician-led, comprehensive clinical care model. Through partnerships with practices, providers, payers, we work to advance the usage of clinical best practices and cutting-edge data analytics to improve outcomes across a continuum of reimbursement models. Panoramic Health's Clinical Research division - Panoramic Science - collaborates with sponsors and clinical research organizations to pioneer cutting-edge treatments for patients with kidney disease. For more information about Panoramic Health and our commitment to transforming kidney care, please visit our website at panoramichealth.com.

Contact Information

Panoramic Health Media
media@panoramichealth.com

SOURCE: Panoramic Health

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.